Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study

Marios Politis, Paola Piccini, Nicola Pavese, Seong Beom Koh, David J. Brooks

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

A mild to moderate reduction in dopamine, noradrenaline and serotonin levels alongside a progressive loss of hypocretin cells and melanin hormone concentrating cells has been reported in the hypothalamus of PD at postmortem. Hypothalamic uptake of 18F-dopa PET, an in vivo marker of dysfunction of monoaminergic neurons, is also significantly reduced in these patients. These data indicate a general impairment of hypothalamic function in PD. Dopamine receptors play an important role in the regulation of hypothalamic pathways. To date, possible changes in hypothalamic D2 receptor availability have not been investigated in PD. The objective in this study was to assess dopamine D2 receptor availability in hypothalamus of patients with idiopathic Parkinson's disease (PD) using positron emission tomography (PET) with 11C-raclopride (RAC). We evaluated D2 binding in RAC PET images of 14 PD patients using both region of interest (ROI) analysis and a voxel based approach. ROIs for the hypothalamus were traced on the subject's MRI co-registered to the PET image. 11C-raclopride binding potentials (BP) for hypothalamus were obtained by applying ROIs onto parametric images. Findings were compared with those of 9 normal controls. We found a significant reduction in the mean hypothalamic RAC BP of the PD patients compared with the normal controls (0.2714 ± 0.06 vs. 0.3861 ± 0.04; mean ± SD; p = 0.0005). ROI results were confirmed with statistical parametric mapping (SPM). Individual hypothalamic BP values of PD patients did not correlate with age, disease duration, disease severity and levodopa equivalent dose. It remains to be ascertained whether the reductions in hypothalamic D2 receptor availability seen in PD are disease related, the results of chronic exposure to levodopa or both. Our results provide further evidence of dopaminergic dysfunction in the hypothalamus in PD, and this may contribute to the development of sleep, endocrine and autonomic disorders.

Original languageEnglish
Pages (from-to)112-116
Number of pages5
JournalExperimental Neurology
Volume214
Issue number1
DOIs
Publication statusPublished - 2008 Nov 1
Externally publishedYes

Fingerprint

Raclopride
Positron-Emission Tomography
Hypothalamus
Parkinson Disease
Dopamine
Levodopa
Dihydroxyphenylalanine
Dopamine D2 Receptors
Dopamine Receptors
Serotonin
Norepinephrine
Sleep
Neurons

Keywords

  • 11C-Raclopride
  • Dopamine D receptors
  • Dopamine D receptors
  • Hypothalamus
  • PD (Parkinson's disease)
  • PET (positron emission tomography)
  • Putamen

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease : An in vivo 11C-raclopride PET study. / Politis, Marios; Piccini, Paola; Pavese, Nicola; Koh, Seong Beom; Brooks, David J.

In: Experimental Neurology, Vol. 214, No. 1, 01.11.2008, p. 112-116.

Research output: Contribution to journalArticle

Politis, Marios ; Piccini, Paola ; Pavese, Nicola ; Koh, Seong Beom ; Brooks, David J. / Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease : An in vivo 11C-raclopride PET study. In: Experimental Neurology. 2008 ; Vol. 214, No. 1. pp. 112-116.
@article{cc3698d180644cd1982b7695465425a1,
title = "Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study",
abstract = "A mild to moderate reduction in dopamine, noradrenaline and serotonin levels alongside a progressive loss of hypocretin cells and melanin hormone concentrating cells has been reported in the hypothalamus of PD at postmortem. Hypothalamic uptake of 18F-dopa PET, an in vivo marker of dysfunction of monoaminergic neurons, is also significantly reduced in these patients. These data indicate a general impairment of hypothalamic function in PD. Dopamine receptors play an important role in the regulation of hypothalamic pathways. To date, possible changes in hypothalamic D2 receptor availability have not been investigated in PD. The objective in this study was to assess dopamine D2 receptor availability in hypothalamus of patients with idiopathic Parkinson's disease (PD) using positron emission tomography (PET) with 11C-raclopride (RAC). We evaluated D2 binding in RAC PET images of 14 PD patients using both region of interest (ROI) analysis and a voxel based approach. ROIs for the hypothalamus were traced on the subject's MRI co-registered to the PET image. 11C-raclopride binding potentials (BP) for hypothalamus were obtained by applying ROIs onto parametric images. Findings were compared with those of 9 normal controls. We found a significant reduction in the mean hypothalamic RAC BP of the PD patients compared with the normal controls (0.2714 ± 0.06 vs. 0.3861 ± 0.04; mean ± SD; p = 0.0005). ROI results were confirmed with statistical parametric mapping (SPM). Individual hypothalamic BP values of PD patients did not correlate with age, disease duration, disease severity and levodopa equivalent dose. It remains to be ascertained whether the reductions in hypothalamic D2 receptor availability seen in PD are disease related, the results of chronic exposure to levodopa or both. Our results provide further evidence of dopaminergic dysfunction in the hypothalamus in PD, and this may contribute to the development of sleep, endocrine and autonomic disorders.",
keywords = "11C-Raclopride, Dopamine D receptors, Dopamine D receptors, Hypothalamus, PD (Parkinson's disease), PET (positron emission tomography), Putamen",
author = "Marios Politis and Paola Piccini and Nicola Pavese and Koh, {Seong Beom} and Brooks, {David J.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/j.expneurol.2008.07.021",
language = "English",
volume = "214",
pages = "112--116",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease

T2 - An in vivo 11C-raclopride PET study

AU - Politis, Marios

AU - Piccini, Paola

AU - Pavese, Nicola

AU - Koh, Seong Beom

AU - Brooks, David J.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - A mild to moderate reduction in dopamine, noradrenaline and serotonin levels alongside a progressive loss of hypocretin cells and melanin hormone concentrating cells has been reported in the hypothalamus of PD at postmortem. Hypothalamic uptake of 18F-dopa PET, an in vivo marker of dysfunction of monoaminergic neurons, is also significantly reduced in these patients. These data indicate a general impairment of hypothalamic function in PD. Dopamine receptors play an important role in the regulation of hypothalamic pathways. To date, possible changes in hypothalamic D2 receptor availability have not been investigated in PD. The objective in this study was to assess dopamine D2 receptor availability in hypothalamus of patients with idiopathic Parkinson's disease (PD) using positron emission tomography (PET) with 11C-raclopride (RAC). We evaluated D2 binding in RAC PET images of 14 PD patients using both region of interest (ROI) analysis and a voxel based approach. ROIs for the hypothalamus were traced on the subject's MRI co-registered to the PET image. 11C-raclopride binding potentials (BP) for hypothalamus were obtained by applying ROIs onto parametric images. Findings were compared with those of 9 normal controls. We found a significant reduction in the mean hypothalamic RAC BP of the PD patients compared with the normal controls (0.2714 ± 0.06 vs. 0.3861 ± 0.04; mean ± SD; p = 0.0005). ROI results were confirmed with statistical parametric mapping (SPM). Individual hypothalamic BP values of PD patients did not correlate with age, disease duration, disease severity and levodopa equivalent dose. It remains to be ascertained whether the reductions in hypothalamic D2 receptor availability seen in PD are disease related, the results of chronic exposure to levodopa or both. Our results provide further evidence of dopaminergic dysfunction in the hypothalamus in PD, and this may contribute to the development of sleep, endocrine and autonomic disorders.

AB - A mild to moderate reduction in dopamine, noradrenaline and serotonin levels alongside a progressive loss of hypocretin cells and melanin hormone concentrating cells has been reported in the hypothalamus of PD at postmortem. Hypothalamic uptake of 18F-dopa PET, an in vivo marker of dysfunction of monoaminergic neurons, is also significantly reduced in these patients. These data indicate a general impairment of hypothalamic function in PD. Dopamine receptors play an important role in the regulation of hypothalamic pathways. To date, possible changes in hypothalamic D2 receptor availability have not been investigated in PD. The objective in this study was to assess dopamine D2 receptor availability in hypothalamus of patients with idiopathic Parkinson's disease (PD) using positron emission tomography (PET) with 11C-raclopride (RAC). We evaluated D2 binding in RAC PET images of 14 PD patients using both region of interest (ROI) analysis and a voxel based approach. ROIs for the hypothalamus were traced on the subject's MRI co-registered to the PET image. 11C-raclopride binding potentials (BP) for hypothalamus were obtained by applying ROIs onto parametric images. Findings were compared with those of 9 normal controls. We found a significant reduction in the mean hypothalamic RAC BP of the PD patients compared with the normal controls (0.2714 ± 0.06 vs. 0.3861 ± 0.04; mean ± SD; p = 0.0005). ROI results were confirmed with statistical parametric mapping (SPM). Individual hypothalamic BP values of PD patients did not correlate with age, disease duration, disease severity and levodopa equivalent dose. It remains to be ascertained whether the reductions in hypothalamic D2 receptor availability seen in PD are disease related, the results of chronic exposure to levodopa or both. Our results provide further evidence of dopaminergic dysfunction in the hypothalamus in PD, and this may contribute to the development of sleep, endocrine and autonomic disorders.

KW - 11C-Raclopride

KW - Dopamine D receptors

KW - Dopamine D receptors

KW - Hypothalamus

KW - PD (Parkinson's disease)

KW - PET (positron emission tomography)

KW - Putamen

UR - http://www.scopus.com/inward/record.url?scp=54049120959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049120959&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2008.07.021

DO - 10.1016/j.expneurol.2008.07.021

M3 - Article

C2 - 18723016

AN - SCOPUS:54049120959

VL - 214

SP - 112

EP - 116

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -